📊 BMEA Key Takeaways
Is Biomea Fusion, Inc. (BMEA) a Good Investment?
Biomea Fusion is a pre-revenue stage pharmaceutical company burning significant cash with minimal revenue generation and substantial operating losses. The company faces critical runway constraints despite maintaining a strong cash position, with operating cash burn of -$56.4M annually against only $46.6M in cash reserves.
Biomea Fusion’s fundamentals are very weak: the company is generating only modest revenue while posting extremely large operating and net losses, with deeply negative margins and returns on capital. Although the balance sheet is not debt-burdened and near-term liquidity is still adequate, the current cash burn appears too high relative to its cash balance, making the business heavily dependent on improving operating performance or raising additional capital.
Why Buy Biomea Fusion, Inc. Stock? BMEA Key Strengths
- Strong liquidity position with $46.6M in cash and 3.18x current ratio
- No long-term debt burden providing financial flexibility
- Early-stage biotech model with R&D focus appropriate for drug development
- Strong current liquidity with a 3.18x current and quick ratio
- No meaningful long-term debt, limiting balance-sheet leverage risk
- Cash balances of $46.64M still provide short-term operating flexibility
BMEA Stock Risks: Biomea Fusion, Inc. Investment Risks
- Severe operating losses of -$71.8M with only $5.4M revenue indicates minimal commercial traction
- Negative free cash flow of -$56.4M annually creates urgent funding need within 12 months
- Extreme negative margins (-1233.5% net margin) indicate business model is not yet viable
- No insider purchases in 90 days suggests lack of management confidence
- High cash burn relative to remaining runway creates existential dilution risk
- Operating and net margins are severely negative, indicating an unsustainable cost structure
- Operating cash flow and free cash flow are deeply negative, implying substantial ongoing cash burn
- Very low equity base relative to losses raises the risk of future dilution or financial strain
Key Metrics to Watch
- Revenue growth trajectory and clinical trial progress
- Monthly cash burn rate and projected runway
- Cash position relative to operating expenses
- Pipeline advancement and regulatory milestones
- Future financing needs and dilution impact
- Quarterly operating cash burn relative to cash and equivalents
- Revenue progression versus operating expense growth
Biomea Fusion, Inc. (BMEA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.18x current ratio provides a solid financial cushion.
BMEA Profit Margin, ROE & Profitability Analysis
BMEA vs Healthcare Sector: How Biomea Fusion, Inc. Compares
How Biomea Fusion, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biomea Fusion, Inc. Stock Overvalued? BMEA Valuation Analysis 2026
Based on fundamental analysis, Biomea Fusion, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biomea Fusion, Inc. Balance Sheet: BMEA Debt, Cash & Liquidity
BMEA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biomea Fusion, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.44 indicates the company is currently unprofitable.
BMEA Revenue Growth, EPS Growth & YoY Performance
BMEA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | $1.2B | -$5.9M | $-0.43 |
| Q2 2022 | $1.1B | -$5.9M | N/A |
| Q1 2022 | $1.1B | -$5.9M | N/A |
| Q3 2021 | $1.1B | -$293.0K | N/A |
| Q2 2021 | $1.1B | -$293.0K | N/A |
| Q1 2021 | $1.1B | -$398.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biomea Fusion, Inc. Dividends, Buybacks & Capital Allocation
BMEA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biomea Fusion, Inc. (CIK: 0001840439)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BMEA
What is the AI rating for BMEA?
Biomea Fusion, Inc. (BMEA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BMEA's key strengths?
Claude: Strong liquidity position with $46.6M in cash and 3.18x current ratio. No long-term debt burden providing financial flexibility. ChatGPT: Strong current liquidity with a 3.18x current and quick ratio. No meaningful long-term debt, limiting balance-sheet leverage risk.
What are the risks of investing in BMEA?
Claude: Severe operating losses of -$71.8M with only $5.4M revenue indicates minimal commercial traction. Negative free cash flow of -$56.4M annually creates urgent funding need within 12 months. ChatGPT: Operating and net margins are severely negative, indicating an unsustainable cost structure. Operating cash flow and free cash flow are deeply negative, implying substantial ongoing cash burn.
What is BMEA's revenue and growth?
Biomea Fusion, Inc. reported revenue of $5.4M.
Does BMEA pay dividends?
Biomea Fusion, Inc. does not currently pay dividends.
Where can I find BMEA SEC filings?
Official SEC filings for Biomea Fusion, Inc. (CIK: 0001840439) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BMEA's EPS?
Biomea Fusion, Inc. has a diluted EPS of $-1.45.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BMEA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Biomea Fusion, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BMEA stock overvalued or undervalued?
Valuation metrics for BMEA: ROE of -425.2% (sector avg: 15%), net margin of -1,233.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BMEA stock in 2026?
Our dual AI analysis gives Biomea Fusion, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BMEA's free cash flow?
Biomea Fusion, Inc.'s operating cash flow is $-56.4M, with capital expenditures of $0.0. FCF margin is -1,048.1%.
How does BMEA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,233.5% (avg: 12%), ROE -425.2% (avg: 15%), current ratio 3.18 (avg: 2).